复方鞘蕊苏颗粒治疗小儿支气管哮喘76例临床疗效分析被引量：2

Clinical observation of Fufangqiaornisu granule in the treatment of 76 children with bronchial asthma

导出

摘要目的研究复方鞘蕊苏颗粒治疗小儿支气管哮喘的临床疗效，为该疾病的治疗提供依据。方法选择入院治疗的152例小儿支气管哮喘患者为研究对象，随机分为两组，对照组单独给予孟鲁司特钠片，观察组给予复方鞘蕊苏颗粒和孟鲁司特钠片联合应用，比较两组临床症状如咳嗽、气喘、湿哕音消失时间和临床总有效率。结果观察组咳嗽、气喘、湿哕音消失的时间分别为（3．8±1．0）d、（3．5±0．8）d和（2．1±0．6）d，明显短于对照组的（5．2±0．7）d、（4．7±0．9）d和（3．0±0．5）d，两组差异均有统计学意义（t=4．56、5．12、4．89，均P〈0．05）；经过治疗，治疗组FVC、FEV，和PEF分别为（4．9±1．7）L、（3．8±0．6）L和（3．9±0．5）L/min，明显好于对照组的（3．2±1．2）L、（2．1±0．8）L和（2．8±0．5）L／min，两组差异均有统计学意义（t=5．12、4．87和5．32，均P〈0．05）；观察组临床总有效率为92．1％，对照组临床有效率为73．7％，两组差异有统计学意义（x2=1．62，P=0．027）。结论复方鞘蕊苏颗粒治疗小儿支气管哮喘临床症状消失快，总有效率高，值得临床推广使用。 Objective To study the clinical effect of Fufangqiaoruisu granule in the treatment of children with bronchial asthma. Methods 152 children with bronchial asthma were randomly divided into treatment group and control group. All the patients were treated with based therapy, and the patients in the control group were treated with montelukast, the patients in the treatment group received montelukast/Fufangqiaoruisu granule. The clinical symptoms such as cough, asthma were compared, and also the total effective rate. Results The disappear time of clinical symp- toms of cough, ashma, moist rale in the treatment group were （ 3.8 ± 1.0 ） days, （ 3.5 ±0. 8 ） days, and （ 2. 1 ±0 6） days, which were much shorter than （ 5.2 ±0.7 ） days, （4.7±0. 9） days, （ 3.0 ± 0.5 ） days in the control group, the differences were statistically significant（ t = 4.56,5.12,4.89, all P 〈 0.05 ）. After treatment, the FVC, FEV1 and PEF in the treatment group were （4.9 ± 1.7） L, （ 3.8 ± 0.6） L and （ 3.9 ± 0.5 ） L/rain, which in the control group were （3.2 ± 1.2） L, （2.1 ±0.8） L and （2.8 ± 0.5 ） L/min, （ t = 5.12,4.87,5.32, all P 〈 0.05 ）. The total effective rate of the observation group was 92.1%, which of the control group was 73.7%, the difference was statistically significant（ X2 = 1.62 ,P = 0. 027 ）. Conclusion Fufangqiaoruisu granule shows satisfactory clinical efficacy in the treatment of bronchial asthma, and it is worthy of clinical use.

作者张居卫姜燕飞张海英

机构地区胶州市人民医院药剂科胶州市九龙办事处九龙卫生院内科

出处《中国基层医药》 CAS 2016年第5期727-729,共3页 Chinese Journal of Primary Medicine and Pharmacy

关键词支气管哮喘儿童复方鞘蕊苏颗粒孟鲁司特 Bronchial asthma Child Fufangqiaoruisu granule Montelukast

分类号 R725.6 [医药卫生—儿科]

引文网络
相关文献

参考文献17

1Aldubi HM, Missa EM, Kamfar HZ, et al. Bronchial asthma and hypovitaminosis D in Saudi children[J]. Asia Pac Allergy,2015, 5 ( 2 ) : 103-113.
2Wechsler ME, Castro M, Lehman E, et al. Impact of race on asthma treatment failures in the asthma clinical research network [ J ]. Am J Respir Crit Care Med, 2011,184 ( 11 ) : 1247-1253.
3Lin J, Yin K, Su N, et al. Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma. [J]. Ann Transl Med,2015,7 ( 11 ) :2061-2078.
4Bozek A, Krajewska J, Jarzab J. The improvement of cognitive functions in patients with bronchial asthma after therapy [ J ]. J Asthma,2010,47 ( 10 ) : 1148-1152.
5Ghosh K A, Tripathi P C. Clinical effect of Virechana and Shamana Chikitsa in Tamaka Shwasa ( Bronchial Asthma) [ J ]. Ayu, 2012,33 (2) :238-242.
6Panda A K, Doddanagali S R. Clinical efficacy of herbal Padmapatradi yoga in bronchial asthma (Tamaka Swasa) [ J]. J Ayurveda Integr Med, 2011,2 ( 2 ) : 85-90.
7Yadav S S, Galib, Patgiri B, et al. Clinical efficacy of two different samples of Shirishavaleha in Tamaka Shwasa (Bronchial Asthma)[J]. Ayu, 2012,33 ( 2 ) : 255-260.
8Agarwal R, Noel V, Aggarwal A N, et al. Clinical significance of AspergiUus sensitisation in bronchial asthma[ J ]. Mycoses,2011, 54(5) :e531-e538.
9Dubey A K,Rajagopala S ,Patel K S. Comparative clinical efficacy of Ashtangavaleha and Vyaghreehareetakee Avaleha on Tamaka Shwasa ( bronchial asthma) in children [J].Ayu, 2014,35 ( 4 ) : 384-390.
10Lal D, Manocha S, Ray A, et al. Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease [ J ]. J Basic Clin Physiol Pharmacol, 2015,26 ( 5 ) : 443-451.

二级参考文献14

1杨慧,向平超.支气管哮喘全球倡议(2012更新版)简介[J].中国医学前沿杂志（电子版）,2013,5(8):25-29. 被引量：22
2Nakamura K, Kitani A, Strober W. Cell contact-dependent immu- nosuppression by CD4 ( + ) CD25 ( + ) regulatory T cells is men- diated by cellsurface-bound transforming growth factor beta[ J ]. J Exp Med,2001,194 (5) :629-644.
3Semik-Orzech A, Barczyk A, Pierzchaia W. The role of interleu- kin17A in inducing neutrophilic inflammation in the pulmonar- ytract[ J]. Pol Merkur Lekarski,2007,22(129) :163-168.
4Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the de- velopment and function of CD4+ CD25+ Regulatory T ceils [ J ]. Nat Immunol,2003,4(4) :330-336.
5Laurence A, Q'shea JJ. T ( H ) -17 differentiation : of mice and men [ J ]. Nat Immunol,2007,8 (9) :903-905.
6Wong CK, Cao J, Yin YB, et al. Interleukin -17A activation on bronchial epithelium and basophils:a novel inflammatory mecha- nism[J]. Eur R espir J,2010,35(4) :883-893.
7Albano GD,Di Sanoal C, Bonanno A, et al. Thl7 immunity in children with allergic asthma and rhinitis: a pharmacologic ap- proach[ J]. PLoS One,2013,8(4) :e58892.
8Korn T, Bettelli E, Oukka M, et al. IL-17 and Thl7 Cells[ J ]. An- nu Rev Immunol,2009,27(4) :485-517.
9Oboki K, Ohno T, Saito H, et al. Thl7 and allergy [ J ]. Allergol Int,2008,57 (2) :121-134.
10Hori S Nomura T, Sakaguchi S. Control of regulatory T cell devel- opment by the transcription factor Foxp3 [ J ]. Science, 2003,299 (5609) :1057-1061.